PCSA
Processa Pharmaceuticals Inc
NASDAQ: PCSA · HEALTHCARE · BIOTECHNOLOGY
$2.70
+1.89% today
Updated 2026-04-30
Market cap
$7.93M
P/E ratio
—
P/S ratio
1,320.06x
EPS (TTM)
$-10.36
Dividend yield
—
52W range
$2 – $20
Volume
0.1M
Processa Pharmaceuticals Inc (PCSA) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
-373.00%
ROA
-158.30%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2010 | $140000.00 | $-160000.00 | -7.14% | -114.29% | -114.29% |
| 2011 | $20000.00 | $-940000.00 | 100.00% | -3,850.00% | -4,700.00% |
| 2012 | $192145.00 | $-2.44M | 30.65% | -1,182.84% | -1,270.15% |
| 2013 | $312480.00 | $-3.07M | 39.84% | -947.68% | -982.05% |
| 2014 | $200201.00 | $-4.53M | 43.43% | -2,078.13% | -2,260.85% |
| 2015 | $113425.00 | $-3.35M | -10.98% | -870.32% | -2,957.22% |
| 2016 | $113425.00 | $-3.35M | -10.98% | 2,372.57% | -2,957.22% |
| 2017 | $5000.00 | $-1.86M | -37.30% | -36,048.66% | -37,126.30% |
| 2018 | $0.00 | $-3.77M | — | — | — |
| 2019 | $0.00 | $-3.36M | — | — | — |
| 2020 | $0.00 | $-19.04M | — | — | — |
| 2021 | $0.00 | $-11.43M | — | — | — |
| 2022 | $0.00 | $-27.42M | — | — | — |
| 2023 | $0.00 | $-11.12M | — | — | — |
| 2024 | $0.00 | $-11.85M | — | — | — |
| 2025 | $0.00 | $-13.56M | — | — | — |